Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Ponatinib Treatment in CML and Ph+ ALL Patients: Real-Life Data from the Czech Registries

Eva Koriťáková, RNDr., PhD, Michael Doubek, MD PhD, Edgar Faber, MD PhD, Daniela Žáčková, MD PhD, Jan M. Horáček, MD PhD, Petra Bělohlávková, MD PhD, Eduard Cmunt, MD PhD, František Folber, MD PhD, Pavel Jindra, MD PhD, Hana Klamová, MD PhD, Zdeněk Kořístek, MD PhD, Lukáš Stejskal, MD, Tomáš Szotkowski, MD PhD, Cyril Šálek, MD PhD, Renata Kellnerová, MD PhD, Marika Chrápavá, Mgr.

Blood (2019) 134 (Supplement_1): 5905.

https://doi.org/10.1182/blood-2019-126395

Published: 2019

Journal Articles

Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Emma I Andersson, MSc, Shady Adnan, MD MSc, Leopold Sellner, MD, Dorine Bellanger, Alexandra Schrader, Giuliano Crispatzu, Henan Zhang, MD, Carlos C Mateos, PhD, Edgar Faber, MD PhD, Steffen Koschmieder, MD, Tim H. Brummendorf, MD PhD, Krister Wennerberg, PhD, Wei Ding, MD PhD, Marc-Henri Stern, MD PhD, Marco Herling, MD, Simon Anders, PhD, Wolfgang Huber, PhD, Thorsten Zenz, MD, Satu Mustjoki, MD, PhD

Blood (2015) 126 (23): 315.

https://doi.org/10.1182/blood.V126.23.315.315

Published: 2015

Journal Articles

Primary T-Prolymphocytic Leukemia (T-PLL) Cells Are Sensitive To BCL-2 and HDAC Inhibitors: Results From High-Throughput Ex Vivo Drug Testing

Emma I Andersson, MSc, Tea Pemovska, MSc, Samuli Eldfors, MSc, Anneli Lauhio, MD, Paavo Pietarinen, MSc, Edgar Faber, MD, PhD, Olli Kallioniemi, MD, PhD, Krister Wennerberg, PhD, Caroline Heckman, PhD, Kimmo Porkka, MD, PhD, Satu Mustjoki, MD, PhD

Blood (2013) 122 (21): 3828.

https://doi.org/10.1182/blood.V122.21.3828.3828

Published: 2013

Journal Articles

Functional Characterization of T- and NK-Cells in Chronic Myeloid Leukemia Patients Treated with Interferon-α Monotherapy.

Mette Matilda Ilander, MSc, Anna Kreutzman, PhD, Peter Rohon, MD, Teresa Melo, MD, Edgar Faber, MD, PhD, Kimmo Porkka, MD, PhD, Jukka Vakkila, MD, PhD, Satu Mustjoki, MD, PhD

Blood (2012) 120 (21): 2782.

https://doi.org/10.1182/blood.V120.21.2782.2782

Published: 2012

Journal Articles

Interferon Alpha Treated Patients with Chronic Myeloid Leukemia (CML) In Prolonged Complete Remission Have Increased Numbers of NK-Cells and Clonal Gamma-Delta T-Cells, and a Distinct Plasma Cytokine Profile.

Anna Kreutzman, MSc, Peter Rohon, MD, Edgar Faber, MD, PhD, Karel Indrak, MD, PhD, Vesa Juvonen, PhD, Veli Kairisto, MD, PhD, Jaroslava Voglova, MD, Marjatta Sinisalo, MD, PhD, Emilia Flochova, MD, PhD, Petteri Arstila, MD, PhD, Kimmo Porkka, MD, PhD, Satu Mustjoki, MD, PhD

Blood (2010) 116 (21): 1201.

https://doi.org/10.1182/blood.V116.21.1201.1201

Published: 2010

Journal Articles

The Outcome of Unselected Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib In the First Line and the Prognostic Value of ELN Defined Responses – Population Based Analysis of 458 Patients Treated Between 2003–2009.

Blood (2010) 116 (21): 1239.

https://doi.org/10.1182/blood.V116.21.1239.1239

Published: 2010

Journal Articles

Bcr-Abl-Independent Activation of Src Kinases Associated with Development of Dasatinib Resistance in a CML Patient.

Jitka Veselovska, MSc, Renata Solna, PhD, Marie Jarosova, PhD, Edgar Faber, MD, PhD, Helena Urbankova, MSc, Milena Holzerova, MSc, Jana Balcarkova, MSc, Karel Indrak, MD, PhD, Vladimir Divoky, PhD

Blood (2008) 112 (11): 1624.

https://doi.org/10.1182/blood.V112.11.1624.1624

Published: 2008

NARROW

Ponatinib Treatment in CML and Ph+ ALL Patients: Real-Life Data from the Czech Registries

Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Primary T-Prolymphocytic Leukemia (T-PLL) Cells Are Sensitive To BCL-2 and HDAC Inhibitors: Results From High-Throughput Ex Vivo Drug Testing

Functional Characterization of T- and NK-Cells in Chronic Myeloid Leukemia Patients Treated with Interferon-α Monotherapy.

Interferon Alpha Treated Patients with Chronic Myeloid Leukemia (CML) In Prolonged Complete Remission Have Increased Numbers of NK-Cells and Clonal Gamma-Delta T-Cells, and a Distinct Plasma Cytokine Profile.

The Outcome of Unselected Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib In the First Line and the Prognostic Value of ELN Defined Responses – Population Based Analysis of 458 Patients Treated Between 2003–2009.

Bcr-Abl-Independent Activation of Src Kinases Associated with Development of Dasatinib Resistance in a CML Patient.

Email alerts

ASH Publications

American Society of Hematology

Ponatinib Treatment in CML and Ph+ ALL Patients: Real-Life Data from the Czech Registries

Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Primary T-Prolymphocytic Leukemia (T-PLL) Cells Are Sensitive To BCL-2 and HDAC Inhibitors: Results From High-Throughput Ex Vivo Drug Testing

Functional Characterization of T- and NK-Cells in Chronic Myeloid Leukemia Patients Treated with Interferon-α Monotherapy.

Interferon Alpha Treated Patients with Chronic Myeloid Leukemia (CML) In Prolonged Complete Remission Have Increased Numbers of NK-Cells and Clonal Gamma-Delta T-Cells, and a Distinct Plasma Cytokine Profile.

The Outcome of Unselected Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib In the First Line and the Prognostic Value of ELN Defined Responses – Population Based Analysis of 458 Patients Treated Between 2003–2009.

Bcr-Abl-Independent Activation of Src Kinases Associated with Development of Dasatinib Resistance in a CML Patient.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only